Mavoglurant

Phase 1Small molecule

YYale University

Mavoglurant is one of 8 small molecule programs targeting Alcohol Consumption. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol ConsumptionRecruiting

NeuroimagingRecruiting

Alcohol ConsumptionPhase 1

Recruiting

NeuroimagingPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Neuroimaging

#DrugCompanyPhaseTrials

Psilocybin

COMPASS Pathways

Phase 2

1 2

Ketalar

AAultman Health Foundation

Phase 1

3 3

Anerem

AAcacia Pharma Ltd

Phase 1

1 4

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Nociceptin Receptor Antagonist

MMclean Hospital

Phase 2

1 6

Mavoglurant

YYale University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Alcohol Consumption

NCT06136195

Clinical

Trials by Indication[1]

MRI1 trial

Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN

Completed·YYale University·Phase 1·NCT03341715·18 enrolled

Neuroimaging1 trial

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Recruiting·YYale University·Phase 1·NCT05203965·80 enrolled

Alcohol Drinking1 trial

Mavoglurant in Alcohol Drinking

Completed·YYale University·Phase 1·NCT03327792·34 enrolled

Alcohol Consumption1 trial

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Recruiting·YYale University·Phase 1·NCT06136195·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Mavoglurant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mavoglurant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mavoglurant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYale University

Mavoglurant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

MRI1 trial

Neuroimaging1 trial

Alcohol Drinking1 trial

Alcohol Consumption1 trial

References

Drug Info

Quick Facts

Related News